Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New stent aims to save lives from aortic tears

NCT ID NCT07268755

Disease control Sponsor: Qingyou Meng Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new stent (Talos) for treating a life-threatening tear in the aorta, the body's main artery. The stent has special features to improve blood flow and reduce complications. 320 adults with aortic dissection will be followed for 2 years to see if the stent helps the artery heal and avoids the need for more procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

320 people

The number who actually took part.

Started

Dec 2024

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

a group with Thoracic Aortic Dissection

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients scheduled for or already receiving the Talos stent; 2. Age ≥18 years, any gender, non-pregnant or non-lactating; 3. Diagnosed with aortic dissection; 4. Presence of a ≥15mm effective proximal landing zone; 5. Having eligible access artery anatomy; 6. Expected survival \>1 year; 7. Capable of understanding the trial purpose, voluntarily participating, signing informed consent, and willing to undergo follow-up. Exclusion Criteria 1. Definitive diagnosis of aortic-related connective tissue disorders (e.g., Marfan syndrome); 2. Subjects with infectious aortic dissection; 3. Documented allergy to nitinol alloys, contrast agents, or related materials; 4. Severe hepatic/renal dysfunction (ALT or AST \>2.5×ULN, serum creatinine \>2×ULN); 5. Uncontrolled severe infections (e.g., bacteremia or septicemia); 6. History of active bleeding, coagulopathy, or refusal of blood transfusion; 7. Malignancy with life expectancy \<1 year; 8. Pregnancy, lactation, or planned pregnancy during the trial; 9. Concurrent participation in other drug/device trials without completing primary endpoints; 10. Poor compliance with anticipated inability to complete follow-up; 11. Other investigator-determined contraindications for endovascular therapy (e.g., unsuitable vascular access, non-cooperation).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thoracic aortic disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aortic disorder Dissection, Thoracic Aorta

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thoracic aortic disease Thoracic aortic dissection

Contacts and locations

Locations

  • Shanghai Jiaotong University

    Shanghai, Shanghai Municipality, 200020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.